Group 1 - The company expects a net profit attributable to shareholders of 380 million to 480 million yuan for 2024, representing a year-on-year growth of 60.03% to 102.14% [1] - The increase in performance is primarily due to the growth in blood product revenue and a low base from the previous year due to goodwill impairment and other asset impairment [1] - The company achieved a plasma collection volume of 522.04 tons in 2024, an increase of 11.71% year-on-year [1] Group 2 - The company is part of China Resources Pharmaceutical, a well-established state-owned enterprise in the pharmaceutical sector, focusing on the strategic area of blood products [2] - The company is actively expanding its plasma collection stations and has a clear plan for station expansion, aiming to enhance its raw plasma supply capacity [2] - In July 2024, the company announced a horizontal acquisition worth 1.82 billion yuan, adding four operational plasma collection stations and expanding into two new provincial regions [2] Group 3 - The blood product industry has high entry barriers, with strict requirements for new plasma stations and a decreasing number of production licenses [3] - The demand for blood products is expected to grow due to the aging population in China, leading to increased clinical needs [3] - As a leading company in the blood product sector, the company is expected to accelerate its station expansion, product development, and merger integration after entering the China Resources system, positioning itself among the top global blood product companies [3]

Financial Performance Expectations - The company expects net profit attributable to shareholders to be between 38,000 and 48,000 thousand yuan, representing a year-on-year growth of 60.03% to 102.14% compared to 23,746 thousand yuan in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 28,374 and 38,374 thousand yuan, indicating a year-on-year increase of 98.32% to 168.22% from 14,307 thousand yuan last year[3]. - Basic earnings per share are expected to be between 0.75 and 0.95 yuan per share, compared to 0.47 yuan per share in the previous year[3]. Revenue and Operational Highlights - The main reason for the performance change is the increase in revenue from blood products and the low base effect from goodwill impairment and other asset impairment in the previous year[5]. - The company achieved a plasma collection volume of 522.04 tons from 16 operating plasma stations, marking an 11.71% year-on-year growth[5]. Non-Recurring Gains and Losses - The estimated impact of non-recurring gains and losses on net profit is approximately 9,626 thousand yuan[5]. Audit and Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm[4]. - The specific data will be detailed in the company's 2024 annual report[7]. Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The report highlights that the blood products industry in China has high entry barriers, and the demand for blood products is expected to grow due to an aging population and increasing clinical applications. The company, as a leading player in the blood products sector, is expected to accelerate its development through internal expansion and external acquisitions after entering the China Resources system [4][5][6]. Summary by Sections Company Overview - The company, Huaren Boya Biological Pharmaceutical Group Co., Ltd., is a leading blood products platform under China Resources, with a comprehensive range of products including human albumin, immunoglobulin, and coagulation factors. The company has undergone several developments since its establishment in 1993 and was officially renamed in 2022 [15][16]. Financial Performance - The company's revenue has shown stability, with blood products revenue increasing from 9.88 billion yuan in 2019 to 14.52 billion yuan in 2023, with a CAGR of 10.10%. The gross margin for blood products has also improved significantly, reaching 69.74% in 2023 [6][31][53]. Market Growth - The blood products market in China has grown rapidly, from 350 billion yuan in 2019 to 544.30 billion yuan in 2023, with a CAGR of 11.67%. The increasing elderly population and expanding clinical applications are driving this growth [5][48]. Product Development - The company is focusing on high-purity immunoglobulin, which is expected to submit a listing application soon. The company has also seen a steady increase in plasma collection, from 372 tons in 2019 to 467.3 tons in 2023, indicating a positive trend for future growth [6][42]. Profitability and Valuation - The projected net profits for the company from 2024 to 2026 are estimated at 5.24 billion yuan, 5.51 billion yuan, and 6.53 billion yuan, respectively. The current price-to-earnings ratios are 27.9, 26.5, and 22.4 for the respective years [4][8].

关于控股股东增持公司股份达到 1%暨后续增持计划的公告 公司控股股东华润医药控股有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 证券代码：300294 证券简称：博雅生物 公告编号：2024-079 华润博雅生物制药集团股份有限公司 1、华润博雅生物制药集团股份有限公司（以下简称公司或博雅生物）控股 股东华润医药控股有限公司（以下简称控股股东或华润医药控股）于 2024 年 11 月8日-12月18日通过深圳证券交易所交易系统以集中竞价交易方式累计增持公 司股份 5,042,400 股，占公司总股本的比例为 1.0000%。 2、华润医药控股自 2024 年 11 月 8 日起 6 个月内拟通过证券法规允许的方 式增持公司股份，总增持股份数量（含本次已增持）不低于总股本的 1%（即 504.24 万股），且不超过总股本的 1.2%（即 605.09 万股）。 截止 2024 年 12 月 18 日，华润医药控股已累计增持公司股份 5,042,400 股， 占公司总股本的比例为 1.00 ...

华润博雅生物制药集团股份有限公司（以下简称公司）全资子公司南京新百 药业有限公司（以下简称新百药业）参加了国家组织药品联合采购办公室（以下 简称联采办）组织的第十批全国药品集中采购的投标工作。新百药业的产品卡前 列素氨丁三醇注射液拟中标本次集中采购。现将相关情况公告如下： 注：1、上述品种的拟中标价格及拟中标数量均以联采办发布的最终数据为准，该产品拟备供地区为江 苏、安徽、陕西、新疆（含兵团）、甘肃、西藏。 证券代码：300294 证券简称：博雅生物 公告编号：2024-078 华润博雅生物制药集团股份有限公司 关于全资子公司参与全国药品集中采购拟中选的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 新百药业此次拟中标产品卡前列素氨丁三醇注射液于 2024 年 8 月获得国家 药品监督管理局核准签发的《药品注册证书》，为新百药业新上市产品，2023 年度尚未实现销售收入。 本次药品集中采购是国家组织的第十批国家药品集中采购，采购周期中，医 疗机构将优先使用本次药品集中采购中选药品，并确保完成约定采购量。新百药 业后续签订采购协议并实施，将进一步扩大相关产品的销 ...

法律意见书——博雅生物 2024 年第四次临时股东大会 北 京 大 成 律 师 事 务 所 关 于 华 润 博 雅 生 物 制 药 集 团 股 份 有 限 公 司 2024 年 第 四 次 临 时 股 东 大 会 的 法 律 意 见 书 www.dachenglaw.com 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16 层 16-21F, Tower B, Zhaotai International Center, 10 Chaoyangmen Nandajie, Chaoyang District, Beijing 100020, China Tel: 8610-58137799 Fax: 8610-58137733 1 北京大成律师事务所关于华润博雅生物制药集团股份有限 公司 2024 年第四次临时股东大会的法律意见书 致：华润博雅生物制药集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公 司股东大会规则》（以下简称"《股东大会规则》"）等法律、法规和其他有关 规范性文件的要求，北京 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-077 华润博雅生物制药集团股份有限公司 2024 年第四次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东大会决议事项的参 与度，本次股东大会对中小投资者进行单独计票，中小投资者是指除上市公司董 事、监事、高级管理人员以及单独或者合计持有公司 5%以上股份的股东以外的 其他股东； 2、本次股东大会不存在增加、变更、否决议案的情况； 3、本次股东大会不存在变更前次股东大会决议的情况； 4、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 华润博雅生物制药集团股份有限公司(以下简称公司)2024 年第四次临时股 东大会通知已于 2024 年 11 月 27 日在中国证券监督管理委员会指定信息披露网 站巨潮资讯网（www.cninfo.com.cn）以公告方式发出。会议于 2024 年 12 月 12 日在江西省抚州市高新技术产业开发区惠泉路 333 号公司会议室以现场与网络 投票相结合的方式召开。本次 ...

Group 1: Business Outlook and Strategy - The blood products sector is a strategic focus for China Resources Pharmaceutical, with a commitment to enhancing the variety, quantity, and quality of blood products [2][4] - The company aims to align with national biological safety strategies and actively undertake tasks related to emerging industries [2][4] - The company has established a clear expansion plan for plasma stations, focusing on potential locations and strategies to enhance raw plasma supply capabilities [4] Group 2: Innovation and Product Development - The company is dedicated to R&D in blood products, with a product pipeline that includes human albumin, immunoglobulin, and coagulation factors [4] - The intravenous immunoglobulin (IVIG) product has received a supplementary application acceptance notice, while the von Willebrand factor (vWF) is in clinical trial stages [4] - The company emphasizes a combination of long-term and short-term R&D innovation strategies, integrating internal and external resources [4] Group 3: Corporate Governance and Financial Policies - China Resources Pharmaceutical has a robust risk compliance system and various management frameworks under its strategic control [2][4] - The company has a proactive and stable profit distribution policy, having implemented its first interim dividend since listing, aimed at increasing dividend frequency and ratio [4] - The company is open to mergers and acquisitions as part of its growth strategy, with a focus on blood products, while acknowledging the uncertainties involved [4]

证券代码：300294 证券简称：博雅生物 公告编号：2024-074 华润博雅生物制药集团股份有限公司 华润博雅生物制药集团股份有限公司（以下简称公司）第八届董事会第七次 会议于 2024 年 11 月 22 日以邮件及通讯方式通知，并于 2024 年 11 月 26 日以通 讯表决的方式召开。会议应参加表决董事 8 人，实参加表决董事 8 人。本次会议 符合《中华人民共和国公司法》《中华人民共和国证券法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》及《公司章程》等相关规定。经充分讨论，审议通过了以下 议案。 二、董事会会议审议情况 1、审议通过《关于增补非独立董事的议案》 鉴于孙金妮女士因工作调动原因提请辞去公司第八届董事会董事、董事会战 略与 ESG 委员会委员职务，根据《公司章程》有关规定，公司董事会成员为九 人，公司将增补一名董事。经公司董事会提名、薪酬与考核委员会任职资格审查 后，公司董事会提名任辉先生为公司非独立董事候选人（简历详见附件），任期 自股东大会审议通过之日起至第八届董事会届满之日止。 本议案在提交董事会审议前已经公 ...

华润博雅生物制药集团股份有限公司 关于增补非独立董事及第八届董事会战略与 ESG 委员会委员的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 华润博雅生物制药集团股份有限公司（以下简称公司）于 2024 年 11 月 26 日召开了第八届董事会第七次会议，审议通过了《关于增补非独立董事的议案》 《关于增补第八届董事会战略与 ESG 委员会委员的议案》，具体情况如下： 鉴于孙金妮女士因工作调动原因提请辞去公司第八届董事会董事、董事会战 略与 ESG 委员会委员职务，根据《公司章程》有关规定，公司董事会成员为九人， 公司将增补一名董事。经公司董事会提名、薪酬与考核委员会任职资格审查后， 公司董事会提名任辉先生为公司非独立董事候选人（简历详见附件）,任期自股 东大会审议通过之日起至第八届董事会届满之日止。 证券代码：300294 证券简称：博雅生物 公告编号：2024-075 为保障董事会专门委员会规范运作，根据相关法律法规，公司董事会提名任 辉先生当选公司董事，并增补其为董事会战略与 ESG 委员会委员，任期自股东大 会审议通过其当选董事之日起至第八届董事会届满之 ...